Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/4855

TDMS Study 96002-02 Pathology Tables

NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00
Route: SKIN APPLICATION                                                                                           Time: 08:19:20

                                                 FINAL#1; 17 DAY REPEATED DOSE




       Facility:  BIORELIANCE

       Chemical CAS #:  136-35-6

       Lock Date:  01/21/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                           5            5            5            5            5            5           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                                                                                  2           
    Natural Death                                                                                                       1           
  Survivors                                                                                                                         
    Terminal Sacrifice                                 5            5            5            5            5            2           
                                                                                                                                    
  Animals Examined Microscopically                     5            5            5            5            5            5           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (5)          (5)          (5)          (5)          (5)          (5)          
      Inflammation, Focal                              5 (100%)     5 (100%)     4 (80%)      1 (20%)      1 (20%)      1 (20%)     
      Necrosis, Focal                                                                                                   2 (40%)     
      Hepatocyte, Vacuolization Cytoplasmic                                                                             1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (5)          (5)          (5)          (5)          (5)          (5)          
      Atrium, Thrombosis                                                                                   1 (20%)      2 (40%)     
      Myocardium, Ventricle, Mineralization                                                                             1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
   Bone Marrow                                        (5)                                                 (5)          (5)          
      Myeloid Cell, Hyperplasia                                                                                         1 (20%)     
   Lymph Node, Mandibular                             (4)          (5)          (5)          (5)          (4)          (4)          
      Atrophy                                                                                                           3 (75%)     
   Lymph Node, Mesenteric                             (5)          (5)          (5)          (5)          (3)          (4)          
      Atrophy                                                                                              1 (33%)      1 (25%)     
   Spleen                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Hematopoietic Cell Proliferation                              5 (100%)     5 (100%)     5 (100%)     2 (40%)      2 (40%)     
      Lymphoid Follicle, Atrophy                                                                           3 (60%)      2 (40%)     
   Thymus                                             (5)          (5)          (5)          (5)          (5)          (4)          
      Atrophy                                                                                 4 (80%)      5 (100%)     3 (75%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (5)          (5)          (5)          (5)          (5)          (5)          
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia                                               5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Hair Follicle, Skin, Site of Application,                                                                                     
           Hyperplasia                                              5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Skin, Site of Application, Inflammation                       5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Skin, Site of Application, Ulcer                                           1 (20%)      2 (40%)      4 (80%)      2 (40%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (5)                                                 (5)          (5)          
      Artery, Inflammation                                                                                              1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Bilateral, Cortex, Renal Tubule, Dilatation                                                                       4 (80%)     
      Bilateral, Cortex, Renal Tubule, Necrosis                                                            4 (80%)      1 (20%)     
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                           5            5            5            5            5            5           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                                                        4            5            5           
  Survivors                                                                                                                         
    Terminal Sacrifice                                 5            5            5            1                                     
                                                                                                                                    
  Animals Examined Microscopically                     5            5            5            5            5            5           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (5)          (5)          (5)          (5)          (5)          (5)          
      Inflammation, Focal                                           4 (80%)      1 (20%)      1 (20%)                   1 (20%)     
      Mineralization                                   1 (20%)                                                                      
      Necrosis, Focal                                                                                      3 (60%)      5 (100%)    
      Hepatocyte, Vacuolization Cytoplasmic                                                                1 (20%)      1 (20%)     
   Stomach, Forestomach                               (5)          (5)          (5)          (5)          (5)          (5)          
      Ulcer, Focal                                                                                         2 (40%)      2 (40%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (5)          (5)          (5)          (5)          (5)          (5)          
      Atrium, Thrombosis                                                                      2 (40%)      5 (100%)     5 (100%)    
      Myocardium, Atrium, Mineralization                                                                                1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Penis                                                                                     (2)          (1)          (1)          
      Congestion                                                                              1 (50%)                               
   Testes                                             (5)          (5)          (5)          (5)          (5)          (5)          
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - CONT                                                                                                               
      Germinal Epithelium, Degeneration                                                                    2 (40%)      1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (5)                       (5)          (5)          (5)          (5)          
      Myeloid Cell, Hyperplasia                                                                            1 (20%)                  
   Lymph Node, Mandibular                             (5)          (5)          (5)          (5)          (4)          (5)          
      Atrophy                                                                                 3 (60%)      4 (100%)     5 (100%)    
   Lymph Node, Mesenteric                             (4)          (5)          (4)          (5)          (5)          (4)          
      Atrophy                                                                                 2 (40%)      3 (60%)      4 (100%)    
   Spleen                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Hematopoietic Cell Proliferation                              5 (100%)     5 (100%)     2 (40%)      1 (20%)                  
      Lymphoid Follicle, Atrophy                                                              1 (20%)      2 (40%)      5 (100%)    
   Thymus                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Atrophy                                                                                 5 (100%)     5 (100%)     5 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (5)          (5)          (5)          (5)          (5)          (5)          
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia                                               5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Epidermis, Skin, Site of Application,                                                                                         
          Inflammation, Focal                          1 (20%)                                                                      
      Hair Follicle, Skin, Site of Application,                                                                                     
           Hyperplasia                                              5 (100%)     5 (100%)     5 (100%)     5 (100%)     2 (40%)     
      Skin, Site of Application, Inflammation                       5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Skin, Site of Application, Ulcer                              1 (20%)      1 (20%)      1 (20%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    6                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
RESPIRATORY SYSTEM - CONT                                                                                                           
   Lung                                               (5)                       (5)          (5)          (5)          (5)          
      Artery, Mineralization                                                                                            1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Bilateral, Cortex, Renal Tubule, Necrosis                                                            5 (100%)     5 (100%)    
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    7                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------